Liu, Y. et al. 2022. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. Journal of Pharmacy & Pharmaceutical Sciences. 25, (Dec. 2022), 377–390. DOI:https://doi.org/10.18433/jpps33020.